Drug Trial Radar · NCT07789327
Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
254
Planned (sponsor's estimate)
Start
Sep 8, 2026
Primary completion
Apr 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Sichuan Huiyu Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 for Injection (Subcutaneous) in participants with advanced solid tumors.
Conditions
- Safety
- Tolerability
- Efficacy
Interventions
Test Product HY07121 for Injection (Subcutaneous)Drug
Dosage form: Powder for solution for infusion. Strength: 10 mg/vial. Method of administration: Subcutaneous administration. Dose escalation: "3+3" dose escalation rules are used to explore the safety and tolerability of the drug HY07121 for Injection (Subcutaneous).Based on emerging clinical data, dose escalation of an SUD-containing regimen may also follow a standard "3+3" design. Dose expansion: according to the preliminary safety and efficacy results of the dose escalation study, an appropriate dose and tumor species for the expansion study are conducted as discussed by the sponsor and investigators to further explore the safety and clinical effectiveness of the drug product HY07121 for Injection (Subcutaneous) and provide a basis for subsequent clinical studies.
Test Product HY07121 for Injection (Subcutaneous)Drug
Dosage form: Powder for solution for infusion. Strength: 10 mg/vial. Method of administration: I Subcutaneous administration. Dose escalation: "3+3" dose escalation rules are used to explore the safety and tolerability of the drug HY07121 for Injection (Subcutaneous).Based on emerging clinical data, dose escalation of an SUD-containing regimen may also follow a standard "3+3" design. Dose expansion: according to the preliminary safety and efficacy results of the dose escalation study, an appropriate dose and tumor species for the expansion study are conducted as discussed by the sponsor and investigators to further explore the safety and clinical effectiveness of the drug product HY07121 for Injection (Subcutaneous) and provide a basis for subsequent clinical studies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation (Part One): Incidence and Nature of Dose-Limiting Toxicity (DLT)Time frame: 28 days during the first 4-week cycle
- Dose Escalation (Part One): Percentage of participants experiencing treatment-emergent adverse events (TEAEs)Time frame: Up to 2 years
- Dose Escalation (Part One): Percentage of participants experiencing Adverse Event (AE) related dose interruptions, dose delays, and dose intensityTime frame: Up to 2 years
- Dose Expansion (Part Two): Objective Response Rate (ORR)Time frame: Up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.